Home > Neurology > AAN 2019 > Epilepsy > Cannabidiol effective in children with Dravet syndrome

Cannabidiol effective in children with Dravet syndrome

Conference
AAN 2019
Trial
GWPCARE
Cannabidiol (CBD) in a dosage of 10 or 20 mg/kg/day significantly reduced convulsive seizure frequency in children and adolescents with Dravet syndrome. This was concluded from GWPCARE, a dose-ranging, multicentre, randomised, double-blind, placebo-controlled trial [1]. CBD20 gave rise to more adverse events and discontinuations. Dravet syndrome is an infantile-onset developmental and epileptic encephalopathy associated with drug-resistant seizures. In GWPCARE, a highly purified form of CBD was applied. The 199 children and adolescents with Dravet syndrome and drug-resistant seizures who participated, had a mean age of 9 years. They were randomised 1:1:1 to placebo or CBD in doses of 10 or 20 mg/kg/day (CBD10 or CBD20) as add-on anticonvulsant therapy. Convulsive seizures during 14 weeks of treatment were reduced 27% in the placebo group, 49% in the CBD10 group (P=0.0095), and 46% in the CBD20 group (P=0.0299). There were also significantly more pat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on